Use of Casirivimab and Imdevimab for the Treatment of COVID-19
Ocala Regional Medical Center
case report, casirivimab, casirivimab and imdevimab, covid-19, imdevimab, monoclonal antibody treatment for covid-19, regen-cov
Emergency Medicine | Therapeutics | Virus Diseases
The authors present three cases of unvaccinated coronavirus disease 2019 (COVID-19) patients who exhibited symptoms of fever, sore throat, nausea, diarrhea, congestion, and headache. Although they refused COVID-19 vaccination, they presented for the casirivimab and imdevimab monoclonal antibody cocktail, which resulted in the resolution of all symptoms. The authors describe the mechanisms and importance of monoclonal antibody treatment for high-risk and unvaccinated patients infected with SARS-CoV-2.
Publisher or Conference
Liu R, Mangal R, Stead TS, Barbera AR, Ganti L. Use of Casirivimab and Imdevimab for the Treatment of COVID-19. Cureus. 2022;14(8):e27766. doi:10.7759/cureus.27766